NCT03833882View on ClinicalTrials.gov

Evaluation of MAF-1217 in Patients With DED

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions
Evaporative Dry Eye Disease
Interventions
DEVICE

MAF1217

The study population will have to self-administer the study treatment in a TID posology.

OTHER

Cationorm

The study population will have to self-administer the study treatment in a TID posology.

Trial Locations (2)

20121

Ospedale San Paolo, ASST Santi Paolo e Carlo, Milan

20157

ASST Fatebenefratelli Sacco P.O.L. Sacco, Milan

All Listed Sponsors
lead

VISUfarma SpA

INDUSTRY

NCT03833882 - Evaluation of MAF-1217 in Patients With DED | Biotech Hunter | Biotech Hunter